Novartis Can't Nix FCA Suit Alleging MS Drug Kickbacks

By Gina Kim · March 31, 2026, 9:41 PM EDT

Novartis must face a False Claims Act suit alleging it improperly had doctors prescribe its multiple sclerosis drug, a New York federal judge said Monday, finding the relator plausibly pled scienter...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

United States of America ex rel. Steven M. Camburn et al. v. Novartis Pharmaceuticals Corporation

Case Number

Court

New York Southern

Nature of Suit

Other Statutes: False Claims Act

Date Filed

May 31, 2013

Recent Articles By Gina

March 27, 2026
Biopharma's Brass Hid Anxiety Drug Trial Risks, Investor Says
March 20, 2026
Feds Rip Ex-NFL Player's New Trial Bid Over Medicare Scheme
March 18, 2026
Philips, Fitbit End Fight Over Health Monitoring Patents
March 12, 2026
Ariz. Docs Ink $4.75M FCA Deal Over Unnecessary Treatment
March 04, 2026
CVS Beats Antitrust Suit Over 340B Drug Program, For Good
February 26, 2026
Kochava, FTC Near Deal To End Geolocation Privacy Suit
February 25, 2026
Online Abortion Pill Provider Illegally Ships To Texas, AG Says
February 20, 2026
Kaiser Sues Insurers To Tap $95M D&O Policy For Fraud Deal
February 13, 2026
Health Exec Says He Was Fired For Opposing 'Enron-Style' Plot
February 03, 2026
Ex-BofA Banker Cops To Role In Medicare Fraud Scheme